Program (as of Oct. 3)
THURSDAY, OCT. 12
Shigeyuki Matsui (Nagoya University, Japan)
Masanori Fukushima (Translational Research Informatics Center, Japan)
Session-1: Design of Phase I Trials
NOC: Nonparametric Overdose Control for Dose Finding.
Phase 1 Clinical Trial Design using Fiducial Inference: Fiducial Toxicity Interval (FTI) Design.
From 3+3 to mTPI: A Collaborative Biostatistician's Experience in a Comprehensive Cancer Center.
Session-2: Early-Phase Combination Trials
Two-Stage Approach Based on Zone and Dose Findings for Two-Agent Combination Phase I/II Trials.
What is the Best Drug Combination for a Patient? Identifying Synergistic Drug Combinations using Ex-Vivo Kinase Inhibitor Screen.
Session-3: Statistical Challenges in Immunotherapy Trials
Statistical Considerations for Immunotherapy Trials in Cancer.
Statistical Considerations in Immuno-oncology Single Arm Trials.
Session-4: Cancer Registry
The International Association for the Study of Lung Cancer Staging Project: History, Classification and Validation.
Trends in Socio-Economic Inequalities in Cancer Outcome in Japan.
Doubly Robust Estimator for Relative Survival in Analyzing Cancer Registry Data.
Session-5: Prognostic Analysis
Practical Methods for Utilization of Biomarkers to Assess Cancer Prognosis
Prediction of Rapid Disease Progression in Multiple Myeloma Based on Genetic and Clinical Factors.
Personalized Prediction of Overall Survival Utilizing Gene Expressions: Approaches Based on the Compound Covariate and a Joint Model.
Yasuo Ohashi (Chuo University, Japan)
FRIDAY, OCT. 13
Haruhiko Fukuda (National Cancer Center, Japan)
Session-6: Analysis of Clinical Trial/Biomarker Data
United Milestone Survival Analysis in Single-Arm Trials.
Follow The Evidence: The Likelihood Ratio and the Single Arm Phase II Clinical Trial
Statistical Inference Based on the Bootstrap Method under Covariate Adaptive Randomization.
Transformation Cure Models for Enrichment Design in Targeted Clinical Trials.
Session-7: Analysis of Molecular Data
iGWAS: A Novel Approach to Discover Genotype-Based Gene Signature of Glioma Risk.
Explaining Cancer Type Specific Mutations with Transcriptomic and Epigenomic Features in Normal Tissues.
Functional Data Classification using Subspace Projection with Application to Mass Spectrometry Data.
Session-8: Adventures in Platform/Umbrella Trials
Lung-MAP: Trials and Tribulations of Designing and Implementing a Multi-Site Umbrella Trial.
Nationwide Genomic Screening, Small Clinical Trials, and Registry for NDAs: Past and Future Directions in SCRUM-Japan Project.
Biomarker Driven Platform Trials: Considerations and a Trial Example.
Motomi Mori (Oregon Health & Science University, USA)